Phase 4 Study

Phase 4 studies are conducted after the test item has been marketed. These studies cannot be conducted until after the FDA has approved the product. The purpose of this phase of clinical research is to provide additional information about the product's safety and efficacy with widespread usage in actual practice. This is the study phase where patients from diverse demographic groups are observed, as the product is available to the general public and there is no need for a control group. Formulations, dosages, treatment durations, and other factors are evaluated. The findings generated by the outcomes of phase 4 study are significant. The detection and identification of previously unknown or inadequately quantified related risk factors and adverse reactions takes place in this study phase. Any side effects associated with long-term use are also determined in this step of the research process. Because these results are concerned with the future, phase 4 study is considered to be prospective.

FDA approved drugs that have been “fast tracked” (approval granted before all conclusive premarketing data has been collected) are mandated to undergo phase 4 testing. The study sponsor must return to earlier phase testing if a new therapeutic indication or different labeling is being sought based on new evidence obtained from findings in this study phase. An example of a phase 4 study might be titled “The Pharmacoeconomics of Short-Term Treatment With Approved Drug X vs. Approved Drug Y in Disease State Patients.”